Affymetrix Announces Research Collaboration With Centre for Proteomic and
Genomic Research (CPGR) in South Africa
SANTA CLARA, Calif. -- November 20, 2012
Affymetrix, Inc. (NASDAQ: AFFX) today announced a research and service
collaboration with the Centre for Proteomic and Genomic Research (CPGR) in
South Africa. CPGR will provide gene expression and Axiom genotyping services
to African researchers using GeneTitan® Multi-Channel (MC) Instrument. The
Affymetrix and CPGR partnership aims to enable high-throughput genomics
research and personalized medicine projects across Africa.
The CPGR is a nonprofit organization funded by the Technology Innovation
Agency (TIA), which is based on an initiative by the Department of Science and
Technology (DST) whose goal is to develop the bio-economy in South Africa.
According to Dr Reinhard Hiller, Managing Director of the CPGR, “The high
throughput capability of GeneTitan^® MC Instrument combined with customizable
Axiom^® Genotyping Arrays is ideal for meeting the needs of scientists in
Africa whose research projects range from small pilot to large-scale discovery
to focused validation studies. GeneTitan^® MC Instrument expands our genomics
service capabilities and will further enable CPGR to support cutting-edge
translational research in Africa. Further, it allows discovery and validation
of disease-related biomarkers economically – even when searching for very rare
genetic variants. We expect to progress personalized medicine studies that aim
to discover genetic markers specific in the African population for better
diagnosis and drug treatment.”
It is a well-known fact that genetic variability of African populations is far
greater than in other regions in the world. This is particularly important
when considering that African populations are underrepresented in most studies
on hereditary diseases and pharmacogenomics. Applying these types of genomic
discoveries to clinical practices has the potential to change health and
wellness of African populations.
“We are excited to partner with CPGR and see this as a significant opportunity
to ensure that African populations are represented in genomics research
studies leading to personalized therapies. Affymetrix is leading the way in
population optimized genotyping analysis and was the first to create a
genotyping array with content derived specifically from African populations,”
said Chris Barbazette, VP of Commercial Operations, International Markets at
Products mentioned in this release are for research use only. Not for
PLEASE NOTE: Affymetrix^®, the Affymetrix logo, Axiom^®, GeneChip^®,
GeneTitan^®, QuantiGene^®, SensationPlus^TM, and all other trademarks are the
property of Affymetrix, Inc. All other trademarks are the property of their
About the CPGR
The CPGR is a specialist not-for-profit contract research organization
established in South Africa through funding by the Technology Innovation
Agency (TIA) to provide support and services to the life science and biotech
community. It is based on an initiative by the Department of Science and
Technology (DST) to boost the development of a bio-economy in South Africa.
The CPGR combines state-of-the-art information rich genomic and proteomic
('omics') technologies with bio-computational pipelines, and biological
models, to create unique solutions in the human health and the agri-biotech
sectors. Please visit www.cpgr.org.za for more information or contact Dr
Reinhard Hiller at email@example.com.
Affymetrix technologies are used by the world's top pharmaceutical,
diagnostic, and biotechnology companies, as well as leading academic,
government, and nonprofit research institutes. More than 26,000 peer-reviewed
papers have been published citing the technologies. Affymetrix is
headquartered in Santa Clara, Calif., and has manufacturing facilities in
Santa Clara, San Diego, Cleveland, Ohio, Singapore, and Austria. The company
has about 1,180 employees worldwide and maintains sales and distribution
operations across Europe, Asia, and Latin America. For more information about
Affymetrix, please visit www.affymetrix.com.
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies" or the like.
Such statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the year ended
December 31, 2011, and other SEC reports for subsequent quarterly periods.
Mindy Lee-Olsen, 408-731-5523
Vice President, Marketing Services
Doug Farrell, 408-731-5285
Vice President, Investor Relations
Press spacebar to pause and continue. Press esc to stop.